Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Iacoboni, Gloria, Villacampa, Guillermo, Martinez‐Cibrian, Nuria, Bailén, Rebeca, Lopez Corral, Lucia, Sanchez, Jose M., Guerreiro, Manuel, Caballero, Ana Carolina, Mussetti, Alberto, Sancho, Juan‐Manuel, Hernani, Rafael, Abrisqueta, Pau, Solano, Carlos, Sureda, Anna, Briones, Javier, Martin Garcia‐Sancho, Alejandro, Kwon, Mi, Reguera‐Ortega, Juan Luis, Barba, Pere
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124109/
https://www.ncbi.nlm.nih.gov/pubmed/33932100
http://dx.doi.org/10.1002/cam4.3881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124109/
https://www.ncbi.nlm.nih.gov/pubmed/33932100
http://dx.doi.org/10.1002/cam4.3881

Ejemplares similares